GSK's Schingles, which boasts the highest efficacy among the existing shingles vaccines, is expected to receive product approval at the end of the year as soon as possible. When Schingles is released in Korea, fierce competition is expected with Zostavax and Sky Zoster.

According to the pharmaceutical industry on the 21st, GSK applied for Schingles item approval from the MFDS in January and is currently undergoing review. Approval is expected within the year, considering the period of time it normally takes for a permit review. It is expected that it will be able to obtain a permit at the latest early next year. Schingles was first approved in the United States in October 2017 and in Europe and Japan.